News und Analysen
![Mylan and Pfizer Finalize Appointments to Viatris Board of Directors](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Mylan and Pfizer Finalize Appointments to Viatris Board of Directors
Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced the remaining appointees to the inaugural 13-member Board of Directors for Viatris, the new company that will result from the
![Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2019, highlighting continued commercial execution, strengthening financial performance and
![LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with Verily, an Alphabet company, to capture measures of depression
![NanoString Technologies Releases Fourth Quarter and Full Year 2019 Operating Results and Provides 2020 Financial Outlook](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
NanoString Technologies Releases Fourth Quarter and Full Year 2019 Operating Results and Provides 2020 Financial Outlook
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today reported financial results for the fourth quarter and year ended December 31
![Healthcare Improvement Company Premier Inc. to Present at Raymond James 41st Annual Institutional Investors Conference in Orlando on March 3](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Healthcare Improvement Company Premier Inc. to Present at Raymond James 41st Annual Institutional Investors Conference in Orlando on March 3
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that its CEO, Susan DeVore, and Chief Administrative and Financial Officer, Craig McKasson, will present at
![Aledade and Humana Announce Broadened Collaboration, Signing Value-Based Agreement for Humana Medicare Members in North Carolina](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Aledade and Humana Announce Broadened Collaboration, Signing Value-Based Agreement for Humana Medicare Members in North Carolina
Aledade, Inc. and leading health and well-being company Humana Inc. (NYSE: HUM) today announced an agreement to expand the availability of value-based care for Humana Medicare Advantage members in
![Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for neratinib in
![Premier Inc. Celebrates a Year of Success in Eliminating Drug Shortages](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Premier Inc. Celebrates a Year of Success in Eliminating Drug Shortages
Premier Inc. (NASDAQ: PINC) today released an annual report on its national drug shortage programs, detailing key accomplishments and successful outcomes that have been achieved in collaboration
![LivaNova Reports Fourth Quarter and Full-Year 2019 Results](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
LivaNova Reports Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019.
For the fourth quarter of
![Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2019 financial results before
![LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the Cowen and Company 40th
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the Cowen and Company 40th
![Premier Inc. Named One of the 2020 World’s Most Ethical Companies® by Ethisphere® Institute for the 13th Year in a Row](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Premier Inc. Named One of the 2020 World’s Most Ethical Companies® by Ethisphere® Institute for the 13th Year in a Row
Premier Inc., a leading healthcare improvement company, has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2020
![Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative
![Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the U.S. Food
![Xencor Reports Fourth Quarter and Full Year 2019 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Xencor Reports Fourth Quarter and Full Year 2019 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
![Dexcom to Present at Cowen 40th Annual Healthcare Conference](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Dexcom to Present at Cowen 40th Annual Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:
-
Steven Pacelli, Executive Vice President, Strategy
![Dexcom to Present at Cowen 40th Annual Healthcare Conference](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Dexcom to Present at Cowen 40th Annual Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:
-
Steven Pacelli, Executive Vice President, Strategy
![Clovis Oncology Announces 2019 Operating Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Clovis Oncology Announces 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2019, and provided an update on Clovis’ clinical development programs and regulatory and
![Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th
![NBC feiert Buyout-Jubiläum mit weiteren Kursgewinnen von bis zu +325%](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
NBC feiert Buyout-Jubiläum mit weiteren Kursgewinnen von bis zu +325%
Vor einem Jahr feierte der No Brainer Club seinen ersten Buyout und damit +303% Kursgewinn über Nacht! Weitere +325% wurden passend zum Jubiläum nun an anderer Stelle eingefahren.
![Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2019. Unless otherwise stated, all comparisons
![First Patient Dosed With Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer With Liver Metastases](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
First Patient Dosed With Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer With Liver Metastases
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the first